Phase II single-arm, single-center clinical trial of all-trans-retinoic acid, bevacizumab, and atezolizumab in refractory microsatellite stable colorectal cancer. A phase 3 study of first-line ...

Researchers identified the enzyme CMPK2 as a possible target for therapies aiming to prevent metabolic dysfunction-associated ...

The combination of sotorasib (Lumakras) and panitumumab (Vectibix) has received FDA approval for the treatment of previously treated KRAS G12C-mutated metastatic colorectal cancer. In the CodeBreaK ...

The multicenter, open-label, CodeBreaK 300 trial of sotorasib plus panitumumab showed consistent efficacy across key subgroups of patients with metastatic colorectal cancer harboring KRAS G12C ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which ... Krazati and Amgen’s Lumakras (sotorasib), which are both approved ...

Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover small-molecule candidates that target the cancer-driving KRAS protein, ...

The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...

Amgen has inaugurated its new drug substance facility in the US after announcing a $1bn further expansion at the North ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...